Skip to main content
U.S. Department of Energy
Office of Scientific and Technical Information

Interest of somatostatin receptors scintigraphy for imaging differentiated thyroid carcinoma tumor sites

Journal Article · · Journal of Nuclear Medicine
OSTI ID:441583
; ;  [1]
  1. Institut Gustave-Roussy, Villejuif (France); and others

Despite the fact that differentiated thyroid carcinoma (DTC) is not classified as a neuroendocrine tumor, there is an increasing interest for the use of somatostatin receptors scintigraphy (SRS) in this disease. We evaluated SRS in DTC patients having no or a poor radioiodine uptake at the level of their tumor sites. Nine patients (pts) (7 men, 2 women; aged from 52 to 65 years) were previously treated (surgery of the primary: 9/9pts; followed by cervical radiotherapy: 4/9pts; radioiodine therapy: 8/9pts; surgery or radiotherapy to bone metastases: 2/9 pts) for DTC (papillary form: 6 pts; follicular; 1 pts; insular: 2 pts). They were explored by conventional imaging modalities (CIM) including Tc-99m MDP bone scans. High activity radioiodine scans were obtained 5 days after I-131 therapy. SRS was carried out during thyroxine therapy using Indium-111 pentetreotide (120 MBq) with imaging at 4 and 24 hours after injection (whole body scans and, when necessary, SPECT). Thyroglobulin blood level ranged from 120 to 60,000ng/ml. SRS was positive at the level of all tumor sites in 8/9 pts; radioiodine scans were negative in 4 pts (1pt with an insular DTC, 3 pt with a papillary DTC), slightly positive in 2 pts (papillary DTC), positive only on part of tumor sites in 1 pts (insular DTC), positive in 1 pt (follicular DTC) and not done in 1 pt. SRS demonstrated 3 new tumor sites (1 to bone, 1 to lung and 1 to mediastinal lymph nodes) in 2 pts; in an other pt, SRS clarified out a doubtful Tc-99m bone scan result and led to definitive confirmation of bone metastases. We had only 1 false negative result in 1 pt having pulmonary metastases (slightly positive radioiodine scan) which had been stable in size on CT for 6 years. These results indicate that, when radioiodine scans are ineffective, SRS is a powerful modality for imaging DTC tumor sites.

OSTI ID:
441583
Report Number(s):
CONF-950603--
Journal Information:
Journal of Nuclear Medicine, Journal Name: Journal of Nuclear Medicine Journal Issue: Suppl.5 Vol. 36; ISSN JNMEAQ; ISSN 0161-5505
Country of Publication:
United States
Language:
English

Similar Records

Radioiodine and radiotherapy in the management of thyroid cancers
Journal Article · Fri Jun 01 00:00:00 EDT 1990 · Otolaryngologic Clinics of North America; (USA) · OSTI ID:6606663

Comparative Uptake Patterns of Radioactive Iodine and [18F]-Fluorodeoxyglucose (FDG) in Metastatic Differentiated Thyroid Cancers
Journal Article · Sat Jul 06 00:00:00 EDT 2024 · Journal of Clinical Medicine · OSTI ID:2470781

Tc-99m-pertechnetate scanning in metastatic thyroid carcinoma: a case report
Journal Article · Tue Mar 31 23:00:00 EST 1981 · Clin. Nucl. Med.; (United States) · OSTI ID:5578413